GlaxoSmithKline has jumped onto the T-cell cancer therapy bandwagon, taking an option with US biotech Adaptimmune to develop a treatment targeting a peptide found on the surface of most can
Cellectis’ 'off the shelf' CAR-T cancer therapy has hit a major setback after the first patient treated in a phase 1 study died, and the first patient treated in another developed life-thr
